China's new crown vaccine enters Phase II clinical trial for 84-year-olds

　　Medicine Network April 15 by the Military Academy of Sciences Institute of Biological Engineering Research Chen Wei team developed adenovirus vector recombinant new coronavirus vaccine, on the 12th to carry out the second phase of clinical trials The World Health Organization's official website announced that this is the world's only current entry into Phase II clinical trials of the new coronavirus vaccine 13 morning, 84-year-old Wuhan Xiong Zhengxing accompanied by his daughter completed the vaccination, becoming the second phase of clinical trials of the oldest volunteer compared to Phase I, adenovirus vector recombinant new coronavirus vaccine Phase II clinical trials released the upper age limit, allowing some older volunteers over the age of 60 to join them Chen Wei said that the new coronary pneumonia patients in the middle and elderly population, the vaccine must be able to provide them with a safe barrier in the process of epidemic prevention and control, China has carried out a variety of technical routes of vaccine research and development, in which adenovirus vector recombination of the new coronavirus vaccine research and development work has made significant progress, is currently in the international leading position Chen Wei introduced, the vaccine to the modified replication of defective adenovirus as a carrier, equipped with the new coronavirus S gene, into the subject body, so that the human body to produce an immune memory of the S protein, so as to achieve the virus "shut out" effect January 26, Chen Wei led the team to Wuhan first-line, with the Beijing rear research base at the same time to fight, to carry out vaccine research and development All 108 volunteers who completed the first phase of the vaccine clinical trial on March 27 have now completed observations and are in good condition adenovirus vector recombinant phase II clinical trial of the neo-coronavirus vaccine will recruit 500 volunteers and introduce a placebo control group to further evaluate the immunogenicity and safety of the vaccine As of 17:00 on the 13th, 273 volunteers had been vaccinated.